Decision ruleHaematology

International Staging System for multiple myeloma (ISS)

Stages multiple myeloma into three stages using serum β2-microglobulin and albumin.

Updated 31 October 2026

When to use it

Patients with newly diagnosed symptomatic multiple myeloma, before treatment.

What it needs

  • Serum β2-microglobulinUnits: mg/L, nmol/L
  • Serum albuminUnits: g/dL, g/L

How to interpret it

ISS stage
ResultInterpretation
≤ 1Stage I: median survival ≈ 62 months
2Stage II: median survival ≈ 44 months
≥ 3Stage III: median survival ≈ 29 months

Practical tip

β2-microglobulin rises with renal impairment, so stage III mixes tumour burden and kidney damage.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top